Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

from Merck Serono following the completion of two phase 2 clinical trials for adecatumumab. Total operating expenses were $13.1 million for the three months ended December 31, 2007, compared to $10.9 million for the same period in 2006. For the three months ended December 31, 2007, Micromet reported a net loss of $3.8 million, or $0.09 per basic and diluted share, compared to net income of $3.4 million, or $0.11 per basic and diluted share, for the same period in 2006. The positive net income in 2006 was due primarily to the milestone payment received from Merck Serono.

Year Ended December 31, 2007

Revenues for the year ended December 31, 2007 were $18.4 million, compared to $27.6 million for 2006. For the year ended December 31, 2007, Micromet reported operating expenses of $43.6 million, compared to $61.2 million for the same period in 2006. In connection with the merger with CancerVax, Micromet recorded a non-recurring, non-cash charge of $20.9 million in the second quarter of 2006 due to the immediate write-off of CancerVax's in- process research and development programs. For the year ended December 31, 2007, net loss was $20.1 million, or $0.55 per basic and diluted share, compared to $34.0 million, or $1.29 per basic and diluted share, for 2006.

Micromet's cash and cash equivalents were $27.1 million as of December 31, 2007. Net cash used in operating activities was $14.3 million for the year ended December 31, 2007 and $15.4 million in 2006. Based on the status of our development programs, management believes that the cash balance at December 31, 2007 is sufficient to fund operations into the second quarter of 2009.

2008 Outlook:

-- Micromet will present an update on its proprietary BiTE antibody

technology platform and new BiTE antibody programs at the conference of

the American Association of Cancer Research (AACR) in April 2008.

-- A phase 1/2 clinical trial evaluating MT103 in patients wi
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... (PRWEB) August 19, 2014 ... to raise $200,000 to fund a corporate lab ... , This development is a critical component ... of care to the implementation of personalized medicine ... of practicing medicine. , Indiegogo contributions will support ...
(Date:8/19/2014)... La Jolla, CA (PRWEB) August 19, 2014 ... the toll Parkinson’s disease can take on an individual. ... tremoring extremities, decreased facial expression, problems swallowing and severe ... due to the dying off of dopamine producing neurons ... retain themselves from a disease that slowly and progressively ...
(Date:8/19/2014)... Research and Markets ... "Spectroscopy Equipment and Accessories - Global Strategic ... This report analyzes the ... in US$ Thousands by the following Product ... NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, IR ...
(Date:8/19/2014)... 2012, the European Union (EU) mandated use of the ICH-recommended ... – responding to the increasing need to understand and manage ... many regions, the main objectives of the PBRER are to:, ... of new or emerging information on the risks of a ... potential benefits of a drug; and , Allow ...
Breaking Biology Technology:Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... SOUTH SAN FRANCISCO, Calif. , April 29 ... creating new therapeutics discovered using cellular reprogramming and directed ... been awarded a three-year $1.5 million "Basic ... (CIRM). The grant will be used to fund the ...
... April 29 HEALTHeCAREERS Network , North America ,s ... , , ... , , , ... Angiography and Interventions (SCAI) recently joined the Network, launching the SCAI ...
... CHICAGO , April 29  Scotland ... attracted many of the world,s leading pharma and biotech ... May 3-6 in Chicago .  Heading ... Scottish research and the nation,s unique integrated industry approach ...
Cached Biology Technology:iPierian Awarded Basic Biology Grant by California Institute of Regenerative Medicine to Study Cellular Reprogramming 2iPierian Awarded Basic Biology Grant by California Institute of Regenerative Medicine to Study Cellular Reprogramming 3Healthcare Web site Expands Reach to Cardiology Professionals 2Healthcare Web site Expands Reach to Cardiology Professionals 3Scotland Announces New Life Science Leadership and Investments at BIO 2010 2Scotland Announces New Life Science Leadership and Investments at BIO 2010 3Scotland Announces New Life Science Leadership and Investments at BIO 2010 4
(Date:8/20/2014)... by researchers at the University of Missouri School of ... life-threatening heart condition caused by muscular dystrophy. , ... Ph.D., the leading author of the study and assistant ... of Molecular Microbiology and Immunology. "This is just a ... a treatment for people with this devastating heart condition, ...
(Date:8/20/2014)... State University researchers have developed methods for electronically manipulating ... electrical signals moths use to control those muscles. The ... moths, or "biobots," for use in emergency response. , ... we can control the movement of moths for use ... Dr. Alper Bozkurt, an assistant professor of electrical and ...
(Date:8/20/2014)... and POINT ROBERTS, Washington , August ... a Key Role in Addressing Security Concerns in the Payment ... global news source covering leading sectors including biometrics, issues commentary ... Jason Peaslee , Managing Partner at Thrive ... Gino Pereira , CEO of NXT-ID, Inc. (OTCBB: NXTD) ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2Research paves way for development of cyborg moth 'biobots' 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7
... explore one of the most critical health/environment intersections how ... diabetes and contribute to the problems of obesity Michigan ... by the Environmental Protection Agency. A five-year, $8 million ... Professor of pathobiology and diagnostic investigation in the College of ...
... Starting rehabilitation sooner following knee arthroplasty surgery could ... physical therapy within 24 hours of surgery can improve ... well as cut hospital stays, according to new research ... SAGE. Mindful of the trend towards discharging patients ...
... CA "Pluripotent" stem cellswhich have the potential to mature ... for their role in treating a vast array of human ... a team of Scripps Research Institute scientists has created a ... for researchers to determine whether their cell lines are normal ...
Cached Biology News:Hold your breath: Air pollution plays role in cardiac, metabolic diseases 2Rehabilitation within a day of knee replacement pays off 2Scripps Research scientists develop new test for 'pluripotent' stem cells 2